- Home
- SONN vs RSLS Comparison
SONN vs RSLS Comparison
Compare SONN & RSLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SONN
- RSLS
- Stock Information
- Founded
- SONN N/A
- RSLS 2002
- Country
- SONN United States
- RSLS United States
- Employees
- SONN N/A
- RSLS N/A
- Industry
- SONN Biotechnology: Pharmaceutical Preparations
- RSLS Medical/Dental Instruments
- Sector
- SONN Health Care
- RSLS Health Care
- Exchange
- SONN Nasdaq
- RSLS Nasdaq
- Market Cap
- SONN 3.8M
- RSLS 4.5M
- IPO Year
- SONN N/A
- RSLS 2007
- Fundamental
- Price
- SONN $1.11
- RSLS $2.56
- Analyst Decision
- SONN Strong Buy
- RSLS Hold
- Analyst Count
- SONN 1
- RSLS 1
- Target Price
- SONN $20.00
- RSLS N/A
- AVG Volume (30 Days)
- SONN 46.3K
- RSLS 7.3M
- Earning Date
- SONN 08-13-2025
- RSLS 08-13-2025
- Dividend Yield
- SONN N/A
- RSLS N/A
- EPS Growth
- SONN N/A
- RSLS N/A
- EPS
- SONN N/A
- RSLS N/A
- Revenue
- SONN $1,000,000.00
- RSLS $7,175,000.00
- Revenue This Year
- SONN $5,376.22
- RSLS $52.80
- Revenue Next Year
- SONN N/A
- RSLS N/A
- P/E Ratio
- SONN N/A
- RSLS N/A
- Revenue Growth
- SONN 978.39
- RSLS N/A
- 52 Week Low
- SONN $1.08
- RSLS $2.23
- 52 Week High
- SONN $10.02
- RSLS $414.99
- Technical
- Relative Strength Index (RSI)
- SONN 38.81
- RSLS 36.91
- Support Level
- SONN $1.11
- RSLS $2.45
- Resistance Level
- SONN $1.25
- RSLS $2.87
- Average True Range (ATR)
- SONN 0.06
- RSLS 0.68
- MACD
- SONN 0.00
- RSLS 0.14
- Stochastic Oscillator
- SONN 0.00
- RSLS 5.45
About SONN Sonnet BioTherapeutics Holdings Inc.
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others.
About RSLS ReShape Lifesciences Inc.
Reshape Lifesciences Inc is a medical device company focused on technologies to treat obesity and metabolic diseases. The company's current portfolio includes the LAP-BAND, an Adjustable Gastric Banding System, ReShapeCare virtual health coaching program, ReShape Market Place, including ReShape Optimize a supplemental multivitamin, the Obalon Balloon System, the first and only swallowable gas-filled balloon system, and the Diabetes Bloc-Stim Neuromodulation, a technology under development as a new treatment for type 2 diabetes mellitus. Geographically, the company operates in the United States, Australia, Europe, and the Rest of world, and the majority of its revenue is generated from the United States.